Arvinas, Inc. (NASDAQ:ARVN) Position Boosted by Rhenman & Partners Asset Management AB

Rhenman & Partners Asset Management AB boosted its position in Arvinas, Inc. (NASDAQ:ARVN) by 19.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 155,500 shares of the company’s stock after buying an additional 25,000 shares during the quarter. Rhenman & Partners Asset Management AB owned approximately 0.23% of Arvinas worth $2,981,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. KBC Group NV grew its position in shares of Arvinas by 77.0% in the 4th quarter. KBC Group NV now owns 2,885 shares of the company’s stock worth $55,000 after acquiring an additional 1,255 shares in the last quarter. Quantbot Technologies LP boosted its holdings in Arvinas by 147.3% in the third quarter. Quantbot Technologies LP now owns 4,367 shares of the company’s stock worth $108,000 after purchasing an additional 2,601 shares during the period. KLP Kapitalforvaltning AS acquired a new position in Arvinas in the fourth quarter worth $171,000. Teacher Retirement System of Texas increased its stake in Arvinas by 19.0% during the fourth quarter. Teacher Retirement System of Texas now owns 14,295 shares of the company’s stock valued at $274,000 after purchasing an additional 2,280 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its holdings in shares of Arvinas by 10.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 14,570 shares of the company’s stock worth $279,000 after purchasing an additional 1,367 shares during the period. Institutional investors and hedge funds own 95.19% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on ARVN shares. Guggenheim lowered their price objective on shares of Arvinas from $57.00 to $32.00 and set a “buy” rating for the company in a research report on Thursday, March 13th. HC Wainwright restated a “buy” rating and issued a $81.00 target price on shares of Arvinas in a research note on Tuesday, March 11th. BMO Capital Markets set a $20.00 price target on Arvinas and gave the stock an “outperform” rating in a research report on Wednesday, March 12th. Oppenheimer downgraded Arvinas from an “outperform” rating to a “market perform” rating in a report on Tuesday, March 11th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Arvinas in a research note on Friday, February 7th. Five analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $35.50.

Arvinas Trading Down 4.9 %

ARVN stock opened at $6.56 on Friday. The firm’s 50-day moving average is $14.15 and its two-hundred day moving average is $20.07. The company has a market capitalization of $451.14 million, a price-to-earnings ratio of -2.37 and a beta of 2.30. Arvinas, Inc. has a 52 week low of $6.24 and a 52 week high of $39.34.

Arvinas (NASDAQ:ARVN) last released its earnings results on Tuesday, February 11th. The company reported ($0.63) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.44. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. During the same period in the prior year, the business earned ($2.53) earnings per share. On average, equities research analysts predict that Arvinas, Inc. will post -3.81 earnings per share for the current year.

Insider Activity

In other Arvinas news, insider Ian Taylor sold 9,020 shares of Arvinas stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $16.71, for a total value of $150,724.20. Following the transaction, the insider now owns 159,121 shares in the company, valued at approximately $2,658,911.91. The trade was a 5.36 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Noah Berkowitz sold 8,658 shares of the company’s stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $8.59, for a total value of $74,372.22. Following the completion of the transaction, the insider now directly owns 110,023 shares in the company, valued at $945,097.57. This represents a 7.30 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 50,230 shares of company stock worth $769,402 over the last 90 days. 5.23% of the stock is currently owned by company insiders.

Arvinas Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.